Publications

2021

Anand P, Guillaumet-Adkins A, Dimitrova V, Yun H, Drier Y, Sotudeh N, et al. Single-cell RNA-seq reveals developmental plasticity with coexisting oncogenic states and immune evasion programs in ETP-ALL. Blood. 2021;137(18):2463-2480.
Rendeiro AF, Casano J, Vorkas CK, Singh H, Morales A, DeSimone RA, et al. Profiling of immune dysfunction in COVID-19 patients allows early prediction of disease progression. Life Sci Alliance. 2021;4(2).
Gill CM, Aktaş E, Alfouzan W, Bourassa L, Brink A, Burnham C-, et al. Elevated MICs of Susceptible Antipseudomonal Cephalosporins in Non-Carbapenemase-Producing, Carbapenem-Resistant Pseudomonas aeruginosa: Implications for Dose Optimization. Antimicrob Agents Chemother. 2021;65(11):e0120421.
Gkrouzman E, Sevim E, Finik J, Andrade D, Pengo V, Sciascia S, et al. Antiphospholipid Antibody Profile Stability Over Time: Prospective Results From the APS ACTION Clinical Database and Repository. J Rheumatol. 2021;48(4):541-547.
Takahashi-Kobayashi M, Usui J, Yaguchi M, Yamazaki S, Kawamura T, Kaneko S, et al. Immunohistological score of transcription factor 21 had a positive correlation with its urinary excretion and proteinuria in immunoglobulin A nephropathy. Histol Histopathol. 2021:18367.
Karkampouna S, La Manna F, Benjak A, Kiener M, De Menna M, Zoni E, et al. Patient-derived xenografts and organoids model therapy response in prostate cancer. Nat Commun. 2021;12(1):1117.
Wang Y, Yan F, Nasar A, Chen Z-, Altorki NK, Stiles B, et al. CUL4 Lung Adenocarcinomas Are Dependent on the CUL4-p21 Ubiquitin Signaling for Proliferation and Survival. Am J Pathol. 2021;191(9):1638-1650.
Ranasinha N, Omer A, Philippou Y, Harriss E, Davies L, Chow K, et al. Ductal adenocarcinoma of the prostate: A systematic review and meta-analysis of incidence, presentation, prognosis, and management. BJUI Compass. 2021;2(1):13-23.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700